<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00942175</url>
  </required_header>
  <id_info>
    <org_study_id>TAK-390MR_101</org_study_id>
    <secondary_id>U1111-1112-6792</secondary_id>
    <nct_id>NCT00942175</nct_id>
  </id_info>
  <brief_title>A Study of the Effects of Multiple Doses of Dexlansoprazole, Lansoprazole, Omeprazole or Esomeprazole on the Pharmacokinetics and Pharmacodynamics of Clopidogrel in Healthy Participants.</brief_title>
  <official_title>A Phase 1, Randomized, Open-Label, 2-Period, Crossover Design Study to Assess the Effects of Multiple Oral Doses of Dexlansoprazole, Lansoprazole, Omeprazole or Esomeprazole on the Steady-State Pharmacokinetics and Pharmacodynamics of Clopidogrel in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Takeda</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Takeda</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the potential effect and safety of multiple oral doses
      of dexlansoprazole, lansoprazole, omeprazole or esomeprazole, once daily (QD), on the
      steady-state pharmacokinetics and pharmacodynamics of clopidogrel, and to assess the safety
      of multiple doses of clopidogrel in healthy participants.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 1, randomized, open-label, single-center, multiple-dose, 2-period, crossover
      study to assess the effects of multiple oral doses of dexlansoprazole, lansoprazole,
      omeprazole or esomeprazole on the steady-state pharmacokinetics (PK) and pharmacodynamics
      (PD) of clopidogrel in healthy participants.

      Participants were randomized equally into eight regimen sequence groups, 20 participants
      each. Participants randomized to Sequence Groups 1 and 2, 3 and 4, 5 and 6 and 7 and 8 were
      called proton pump inhibitor (PPI) Groups 1, 2, 3, and 4, respectively. Each sequence group
      consists of 2 regimens. Sequence Groups 1, 3, 5 and 7 dosed Regimen A (75 mg clopidogrel) for
      Days 1-9 of Period 1 and then crossed over to one of the following 4 regimens for Days 1-9 of
      Period 2: Regimen B (75 mg clopidogrel + 30 mg lansoprazole), Regimen C (75 mg clopidogrel +
      60 mg dexlansoprazole), Regimen D (75 mg clopidogrel + 80 mg [2x40 mg] omeprazole), or
      Regimen E (75 mg clopidogrel + 40 mg esomeprazole). Sequence Groups 2, 4, 6 and 8 began with
      either Regimen B, C, D or E for Period 1 and then crossed over to Regimen A for Period 2.

      On Day 9 of each period, blood samples were collected at predose and for 24 hours postdose to
      measure plasma concentrations of the active metabolite of clopidogrel. Platelet function was
      assessed daily prior to the dose of clopidogrel on Days 7-9 and 24-hours post Day 9 dose in
      each period. There was a washout interval of 10 to 14 days between the last dose of study
      drug in Period 1 and the first dose of study drug in Period 2.

      Study participants were confined to the study center for 10 consecutive nights in Period 1,
      followed by a 10- to 14-day washout interval and confined for an additional 10 consecutive
      nights in Period 2.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2009</start_date>
  <completion_date type="Actual">July 2010</completion_date>
  <primary_completion_date type="Actual">June 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetic Parameter Peak Plasma Concentration (Cmax) of Clopidogrel's Active Metabolite.</measure>
    <time_frame>Day 9 of each period</time_frame>
    <description>Maximum observed plasma concentration (Cmax) is the peak plasma concentration of a drug after administration, obtained directly from the plasma concentration-time curve.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic Parameter Area Under the Plasma Concentration Versus Time Curve (AUC) From Time 0 to Time of the Last Quantifiable Concentration (AUC[0-tlqc]) of Clopidogrel's Active Metabolite.</measure>
    <time_frame>Day 9 of each period</time_frame>
    <description>Area under the plasma concentration versus time curve (AUC(0-tlqc)) is a measure of total plasma exposure to the drug from Time 0 to Time of the Last Quantifiable Concentration (AUC[0-tlqc]).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacodynamic Parameter Platelet Reactivity Index (PRI) From Vasodilator-stimulated Phosphoprotein (VASP) Phosphorylation State (Flow Cytometry).</measure>
    <time_frame>24-hour post Day 9 dose in each period.</time_frame>
    <description>PRI is the platelet reactivity index from VASP phosphorylation state (flow cytometry).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacodynamic Parameter Maximum Platelet Aggregation (MPA) From Aggregometry (Turbidimetric) With 5 µM Adenosine Diphosphate.</measure>
    <time_frame>24-hour post Day 9 dose in each period.</time_frame>
    <description>Maximum platelet aggregation (MPA) from aggregometry (turbidimetric) with 5 µM adenosine diphosphate.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacodynamic Parameter MPA From Aggregometry (Turbidimetric) With 20 µM Adenosine Diphosphate.</measure>
    <time_frame>24-hour post Day 9 dose in each period.</time_frame>
    <description>MPA from aggregometry (turbidimetric) with 20 µM adenosine diphosphate.</description>
  </primary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">160</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Regimen A</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Clopidogrel 75 mg QD</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Regimen B</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Clopidogrel 75 mg QD and Lansoprazole 30 mg QD</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Regimen C</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Clopidogrel 75 mg QD and Dexlansoprazole 60 mg QD</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Regimen D</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Clopidogrel 75 mg QD and Omeprazole 80 mg QD</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Regimen E</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Clopidogrel 75 mg QD and Esomeprazole 40 mg QD</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clopidogrel</intervention_name>
    <description>Clopidogrel 75 mg, tablets, orally, once daily days 1-9.</description>
    <arm_group_label>Regimen A</arm_group_label>
    <other_name>Plavix</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clopidogrel and Lansoprazole</intervention_name>
    <description>Clopidogrel 75 mg, tablets, orally, once daily and Lansoprazole 30 mg, capsules, orally, once daily days 1-9.</description>
    <arm_group_label>Regimen B</arm_group_label>
    <other_name>Plavix</other_name>
    <other_name>Prevacid</other_name>
    <other_name>AG-1749</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clopidogrel and Dexlansoprazole</intervention_name>
    <description>Clopidogrel 75 mg, tablets, orally, once daily and Dexlansoprazole 60 mg, capsules, orally, once daily days 1-9.</description>
    <arm_group_label>Regimen C</arm_group_label>
    <other_name>Plavix</other_name>
    <other_name>Kapidex</other_name>
    <other_name>TAK-390MR</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clopidogrel and Omeprazole</intervention_name>
    <description>Clopidogrel 75 mg, tablets, orally, once daily and Omeprazole 80 mg, capsules, orally, once daily days 1-9.</description>
    <arm_group_label>Regimen D</arm_group_label>
    <other_name>Plavix</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clopidogrel and Esomeprazole</intervention_name>
    <description>Clopidogrel 75 mg, tablets, orally, once daily and Esomeprazole 40 mg, capsules, orally, once daily days 1-9.</description>
    <arm_group_label>Regimen E</arm_group_label>
    <other_name>Plavix</other_name>
    <other_name>Nexium</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. The participant or the participant's legally acceptable representative signs a
             written, informed consent form prior to the initiation of any study procedures.

          2. Weighs at least 50 kg and has a body mass index (BMI) between 18 and 30 kg/m2,
             inclusive, at Screening and Check-in (Day -1 of Period 1) Visits.

          3. Must be a CYP2C19 extensive metabolizer (wt/wt).

          4. Females cannot be nursing and must have a negative urine pregnancy test at Day -1 or
             be of non-childbearing potential. If females are of child bearing potential, must have
             a negative serum human chorionic gonadotropin (hCG) pregnancy test during Screening
             and on an acceptable form of contraception, or have had bilateral tubal ligation if
             performed a minimum of 90 days prior to Day 1.

          5. At the Screening and Check-in (Day -1 of Period 1) Visits, must have an estimated
             creatinine clearance (CLcr) greater than or equal 90 mL/minute as determined from the
             Cockcroft-Gault formula.

          6. Is in good health as determined by a physician based upon medical history,
             electrocardiogram, and physical examination findings at the Screening and Check-in
             (Day -1 of Period 1) Visits.

          7. Participant's clinical laboratory evaluations (including hematology, clinical
             chemistry [fasted for a least 8 hours], and urinalysis) at the Screening and Check-in
             (Day -1 of Period 1) Visits are within the reference range for the testing laboratory
             or are deemed not clinically significant by the investigator and TGRD Medical Monitor.

          8. Participant's urine drug screen for selected substances of abuse is negative at the
             Screening and Check-in (Day -1 of Period 1) Visits.

        Exclusion Criteria:

          1. Has consumed products containing Seville oranges (sour), grapefruit or grapefruit
             juice within 14 days prior to the first dose of study drug or is unwilling to agree to
             abstain from products containing Seville oranges (sour), grapefruit or grapefruit
             juice while participating in the study.

          2. Has current or recent (within 6 months) gastrointestinal disease, a history of
             malabsorption, esophageal reflux, gastric bleeding or peptic ulcer disease, frequent
             (more than once per week) occurrence of heartburn, or any surgical intervention (eg,
             cholecystectomy), which would be expected to influence the absorption of drugs.

          3. Has a history of drug abuse (defined as any illicit drug use) or a history of alcohol
             abuse (defined as the consumption of more than 4 alcoholic beverages per day) within 1
             year prior to the Screening Visit or is unwilling to agree to abstain from alcohol and
             drugs throughout the study.

          4. Is currently participating in another investigational study or has received any
             investigational compound within 30 days prior to the Check-in (Day -1 of Period 1)
             Visit.

          5. Has received any known hepatic or renal clearance altering agents (eg, erythromycin,
             cimetidine, barbiturates, phenothiazines, fluvoxamine, etc.) within 28 days prior to
             first dose of study drug.

          6. Has a history or clinical manifestations of significant metabolic, hematologic,
             pulmonary, cardiovascular, gastrointestinal, neurologic, hepatic, renal, urologic,
             immunologic, or psychiatric disorder as determined by the investigator which may
             impact the ability of the participant to take part in or potentially confound the
             trial results.

          7. Has a history of hypersensitivity or allergies to any drug or food or any excipients
             of clopidogrel, lansoprazole, dexlansoprazole, omeprazole, esomeprazole or other drug
             with the same mechanism of action or related compounds.

          8. Has had an acute, clinically significant illness within 30 days prior to the first
             dose of study drug.

          9. Has a systolic blood pressure greater than 140 mm Hg or has a diastolic blood pressure
             greater than 90 mm Hg at Screening or Check-in (Day -1 of Period 1).

         10. Has a positive test result for hepatitis B surface antigen (HBsAg) or antibody to
             hepatitis C virus (anti-HCV) at Screening, or a known history of infection with the
             human immunodeficiency virus (HIV).

         11. Has a Day -1 laboratory value assessed by the principal investigator and sponsor
             medical monitor as clinically significant underlying disease or condition that may
             prevent the participant from entering the study.

         12. Has an alanine aminotransferase, aspartate aminotransferase or Total Bilirubin level
             that exceeds the upper limit of normal at the Screening or Check-in (Day -1 of Period
             1) Visits.

         13. Has used nicotine-containing products (including but not limited to cigarettes, pipes,
             cigars, chewing tobacco, nicotine patch or nicotine gum) within 6 weeks prior to
             Check-in (Day -1 of Period 1) Visit, or has a positive cotinine screen at the
             Screening or Check-in (Day - 1 of Period 1) Visits or anticipates an inability to
             abstain from these products for the duration of the study.

         14. With the exception of acetaminophen, has taken any excluded medication, supplements or
             food products listed in the Excluded Dietary Items and Medications table located in
             the study protocol.

         15. Has donated blood products (such as plasma) within 30 days, or has donated whole blood
             or had a significant blood loss (500 mL) within 56 days of the first dose of study
             drug

         16. Has a positive test result for caffeine at the Check-in (Day -1 of Period 1) Visit.

         17. Has a history of cancer, except basal cell carcinoma, which has not been in remission
             for at least 5 years prior to the first dose of study drug.

         18. Has received clopidogrel or any PPIs or histamine2-receptor antagonists within 28 days
             of screening.

         19. Participant, in the opinion of the investigator, is unlikely to comply with the
             protocol or is unsuitable for any other reason.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director Clinical Science</last_name>
    <role>Study Director</role>
    <affiliation>Takeda</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Tempe</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://general.takedapharm.com/content/file/pi.pdf?applicationcode=9efb34b3-fb69-4190-a2be-a90b8cb94e25&amp;filetypecode=DEXILANTPI</url>
    <description>Dexilant Package Insert</description>
  </link>
  <link>
    <url>http://www.fda.gov/MEDWATCH/safety.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <verification_date>February 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 16, 2009</study_first_submitted>
  <study_first_submitted_qc>July 17, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 20, 2009</study_first_posted>
  <results_first_submitted>May 31, 2011</results_first_submitted>
  <results_first_submitted_qc>August 3, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 7, 2011</results_first_posted>
  <last_update_submitted>February 1, 2012</last_update_submitted>
  <last_update_submitted_qc>February 1, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 3, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pharmacology</keyword>
  <keyword>Stomach Ulcer</keyword>
  <keyword>Esophagitis, Peptic</keyword>
  <keyword>Zollinger-Ellison Syndrome</keyword>
  <keyword>Platelet function</keyword>
  <keyword>PPI</keyword>
  <keyword>clopidogrel</keyword>
  <keyword>Pharmacokinetics and Pharmacodynamics</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clopidogrel</mesh_term>
    <mesh_term>Ticlopidine</mesh_term>
    <mesh_term>Omeprazole</mesh_term>
    <mesh_term>Esomeprazole</mesh_term>
    <mesh_term>Lansoprazole</mesh_term>
    <mesh_term>Dexlansoprazole</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants enrolled at one site in the United States from 15 December 2009 to 08 July 2010.</recruitment_details>
      <pre_assignment_details>Healthy participants were enrolled in one of 4, once-daily (QD), proton pump inhibitor (PPI) treatment groups.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>PPI Group 1</title>
          <description>Regimen A: Clopidogrel 75 mg, tablets, orally, once daily for up to 9 days.
Regimen B: Clopidogrel 75 mg, tablets, orally, once daily and Lansoprazole 30 mg, capsules, orally, once daily for up to 9 days.</description>
        </group>
        <group group_id="P2">
          <title>PPI Group 2</title>
          <description>Regimen A: Clopidogrel 75 mg, tablets, orally, once daily for up to 9 days.
Regimen C: Clopidogrel 75 mg, tablets, orally, once daily and Dexlansoprazole 60 mg, capsules, orally, once daily for up to 9 days.</description>
        </group>
        <group group_id="P3">
          <title>PPI Group 3</title>
          <description>Regimen A: Clopidogrel 75 mg, tablets, orally, once daily for up to 9 days.
Regimen D: Clopidogrel 75 mg, tablets, orally, once daily and Omeprazole 80 mg, capsules, orally, once daily for up to 9 days.</description>
        </group>
        <group group_id="P4">
          <title>PPI Group 4</title>
          <description>Regimen A: Clopidogrel 75 mg, tablets, orally, once daily for up to 9 days.
Regimen E: Clopidogrel 75 mg, tablets, orally, once daily and Esomeprazole 40 mg, capsules, orally, once daily for up to 9 days.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
                <participants group_id="P2" count="40"/>
                <participants group_id="P3" count="40"/>
                <participants group_id="P4" count="40"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="38"/>
                <participants group_id="P2" count="36"/>
                <participants group_id="P3" count="38"/>
                <participants group_id="P4" count="38"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Elevated Alanine Amino Transferase</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Low Platelet Count</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>PPI Group 1</title>
          <description>Regimen A: Clopidogrel 75 mg, tablets, orally, once daily for up to 9 days.
Regimen B: Clopidogrel 75 mg, tablets, orally, once daily and Lansoprazole 30 mg, capsules, orally, once daily for up to 9 days.</description>
        </group>
        <group group_id="B2">
          <title>PPI Group 2</title>
          <description>Regimen A: Clopidogrel 75 mg, tablets, orally, once daily for up to 9 days.
Regimen C: Clopidogrel 75 mg, tablets, orally, once daily and Dexlansoprazole 60 mg, capsules, orally, once daily for up to 9 days.</description>
        </group>
        <group group_id="B3">
          <title>PPI Group 3</title>
          <description>Regimen A: Clopidogrel 75 mg, tablets, orally, once daily for up to 9 days.
Regimen D: Clopidogrel 75 mg, tablets, orally, once daily and Omeprazole 80 mg, capsules, orally, once daily for up to 9 days.</description>
        </group>
        <group group_id="B4">
          <title>PPI Group 4</title>
          <description>Regimen A: Clopidogrel 75 mg, tablets, orally, once daily for up to 9 days.
Regimen E: Clopidogrel 75 mg, tablets, orally, once daily and Esomeprazole 40 mg, capsules, orally, once daily for up to 9 days.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="40"/>
            <count group_id="B2" value="40"/>
            <count group_id="B3" value="40"/>
            <count group_id="B4" value="40"/>
            <count group_id="B5" value="160"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32.8" spread="6.48"/>
                    <measurement group_id="B2" value="35.7" spread="7.92"/>
                    <measurement group_id="B3" value="34.0" spread="7.40"/>
                    <measurement group_id="B4" value="33.3" spread="7.10"/>
                    <measurement group_id="B5" value="33.9" spread="7.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="20"/>
                    <measurement group_id="B4" value="20"/>
                    <measurement group_id="B5" value="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="20"/>
                    <measurement group_id="B4" value="20"/>
                    <measurement group_id="B5" value="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Pharmacokinetic Parameter Peak Plasma Concentration (Cmax) of Clopidogrel’s Active Metabolite.</title>
        <description>Maximum observed plasma concentration (Cmax) is the peak plasma concentration of a drug after administration, obtained directly from the plasma concentration-time curve.</description>
        <time_frame>Day 9 of each period</time_frame>
        <population>All participants who had valid parameter estimates for both regimens within a PPI group were included in the pharmacokinetics (PK) statistical analyses for this parameter.</population>
        <group_list>
          <group group_id="O1">
            <title>PPI Group 1: Regimen A</title>
            <description>Clopidogrel 75 mg, tablets, orally, once daily for up to 9 days.</description>
          </group>
          <group group_id="O2">
            <title>PPI Group 1: Regimen B</title>
            <description>Clopidogrel 75 mg, tablets, orally, once daily and Lansoprazole 30 mg, capsules, orally, once daily for up to 9 days.</description>
          </group>
          <group group_id="O3">
            <title>PPI Group 2: Regimen A</title>
            <description>Clopidogrel 75 mg, tablets, orally, once daily for up to 9 days.</description>
          </group>
          <group group_id="O4">
            <title>PPI Group 2: Regimen C</title>
            <description>Clopidogrel 75 mg, tablets, orally, once daily and Dexlansoprazole 60 mg, capsules, orally, once daily for up to 9 days.</description>
          </group>
          <group group_id="O5">
            <title>PPI Group 3: Regimen A</title>
            <description>Clopidogrel 75 mg, tablets, orally, once daily for up to 9 days.</description>
          </group>
          <group group_id="O6">
            <title>PPI Group 3: Regimen D</title>
            <description>Clopidogrel 75 mg, tablets, orally, once daily and Omeprazole 80 mg, capsules, orally, once daily for up to 9 days.</description>
          </group>
          <group group_id="O7">
            <title>PPI Group 4: Regimen A</title>
            <description>Clopidogrel 75 mg, tablets, orally, once daily for up to 9 days.</description>
          </group>
          <group group_id="O8">
            <title>PPI Group 4: Regimen E</title>
            <description>Clopidogrel 75 mg, tablets, orally, once daily and Esomeprazole 40 mg, capsules, orally, once daily for up to 9 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetic Parameter Peak Plasma Concentration (Cmax) of Clopidogrel’s Active Metabolite.</title>
          <description>Maximum observed plasma concentration (Cmax) is the peak plasma concentration of a drug after administration, obtained directly from the plasma concentration-time curve.</description>
          <population>All participants who had valid parameter estimates for both regimens within a PPI group were included in the pharmacokinetics (PK) statistical analyses for this parameter.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="38"/>
                <count group_id="O3" value="36"/>
                <count group_id="O4" value="36"/>
                <count group_id="O5" value="38"/>
                <count group_id="O6" value="38"/>
                <count group_id="O7" value="38"/>
                <count group_id="O8" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.14" spread="12.553"/>
                    <measurement group_id="O2" value="30.01" spread="15.264"/>
                    <measurement group_id="O3" value="38.85" spread="15.699"/>
                    <measurement group_id="O4" value="29.33" spread="12.400"/>
                    <measurement group_id="O5" value="38.25" spread="12.461"/>
                    <measurement group_id="O6" value="22.55" spread="10.682"/>
                    <measurement group_id="O7" value="40.98" spread="22.908"/>
                    <measurement group_id="O8" value="24.69" spread="10.641"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.7000</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.6106</ci_lower_limit>
            <ci_upper_limit>0.8026</ci_upper_limit>
            <estimate_desc>The mean difference refers to the point estimates of the relative bioavailability. With its confidence intervals, it was obtained from the ANOVA model on the natural logarithm transformed data.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.7340</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.6516</ci_lower_limit>
            <ci_upper_limit>0.8269</ci_upper_limit>
            <estimate_desc>The mean difference refers to the point estimates of the relative bioavailability. With its confidence intervals, it was obtained from the ANOVA model on the natural logarithm transformed data.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.5564</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.4877</ci_lower_limit>
            <ci_upper_limit>0.6347</ci_upper_limit>
            <estimate_desc>The mean difference refers to the point estimates of the relative bioavailability. With its confidence intervals, it was obtained from the ANOVA model on the natural logarithm transformed data.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.6783</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.5063</ci_lower_limit>
            <ci_upper_limit>0.9087</ci_upper_limit>
            <estimate_desc>The mean difference refers to the point estimates of the relative bioavailability. With its confidence intervals, it was obtained from the ANOVA model on the natural logarithm transformed data.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Pharmacokinetic Parameter Area Under the Plasma Concentration Versus Time Curve (AUC) From Time 0 to Time of the Last Quantifiable Concentration (AUC[0-tlqc]) of Clopidogrel’s Active Metabolite.</title>
        <description>Area under the plasma concentration versus time curve (AUC(0-tlqc)) is a measure of total plasma exposure to the drug from Time 0 to Time of the Last Quantifiable Concentration (AUC[0-tlqc]).</description>
        <time_frame>Day 9 of each period</time_frame>
        <population>All participants who had valid parameter estimates for both formulations within PPI groups were included in the PK statistical analyses for those parameters.</population>
        <group_list>
          <group group_id="O1">
            <title>PPI Group 1: Regimen A</title>
            <description>Clopidogrel 75 mg, tablets, orally, once daily for up to 9 days.</description>
          </group>
          <group group_id="O2">
            <title>PPI Group 1: Regimen B</title>
            <description>Clopidogrel 75 mg, tablets, orally, once daily and Lansoprazole 30 mg, capsules, orally, once daily for up to 9 days.</description>
          </group>
          <group group_id="O3">
            <title>PPI Group 2: Regimen A</title>
            <description>Clopidogrel 75 mg, tablets, orally, once daily for up to 9 days.</description>
          </group>
          <group group_id="O4">
            <title>PPI Group 2: Regimen C</title>
            <description>Clopidogrel 75 mg, tablets, orally, once daily and Dexlansoprazole 60 mg, capsules, orally, once daily for up to 9 days.</description>
          </group>
          <group group_id="O5">
            <title>PPI Group 3: Regimen A</title>
            <description>Clopidogrel 75 mg, tablets, orally, once daily for up to 9 days.</description>
          </group>
          <group group_id="O6">
            <title>PPI Group 3: Regimen D</title>
            <description>Clopidogrel 75 mg, tablets, orally, once daily and Omeprazole 80 mg, capsules, orally, once daily for up to 9 days.</description>
          </group>
          <group group_id="O7">
            <title>PPI Group 4: Regimen A</title>
            <description>Clopidogrel 75 mg, tablets, orally, once daily for up to 9 days.</description>
          </group>
          <group group_id="O8">
            <title>PPI Group 4: Regimen E</title>
            <description>Clopidogrel 75 mg, tablets, orally, once daily and Esomeprazole 40 mg, capsules, orally, once daily for up to 9 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetic Parameter Area Under the Plasma Concentration Versus Time Curve (AUC) From Time 0 to Time of the Last Quantifiable Concentration (AUC[0-tlqc]) of Clopidogrel’s Active Metabolite.</title>
          <description>Area under the plasma concentration versus time curve (AUC(0-tlqc)) is a measure of total plasma exposure to the drug from Time 0 to Time of the Last Quantifiable Concentration (AUC[0-tlqc]).</description>
          <population>All participants who had valid parameter estimates for both formulations within PPI groups were included in the PK statistical analyses for those parameters.</population>
          <units>ng*hr/ML</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="38"/>
                <count group_id="O3" value="36"/>
                <count group_id="O4" value="36"/>
                <count group_id="O5" value="38"/>
                <count group_id="O6" value="38"/>
                <count group_id="O7" value="38"/>
                <count group_id="O8" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.69" spread="10.020"/>
                    <measurement group_id="O2" value="36.42" spread="10.825"/>
                    <measurement group_id="O3" value="41.25" spread="14.690"/>
                    <measurement group_id="O4" value="37.75" spread="13.132"/>
                    <measurement group_id="O5" value="37.78" spread="12.043"/>
                    <measurement group_id="O6" value="26.28" spread="8.800"/>
                    <measurement group_id="O7" value="42.35" spread="18.785"/>
                    <measurement group_id="O8" value="31.23" spread="9.938"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.8573</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.8020</ci_lower_limit>
            <ci_upper_limit>0.9165</ci_upper_limit>
            <estimate_desc>The mean difference refers to the point estimates of the relative bioavailability. With its confidence intervals, it was obtained from the ANOVA model on the natural logarithm transformed data.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.9103</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.8567</ci_lower_limit>
            <ci_upper_limit>0.9672</ci_upper_limit>
            <estimate_desc>The mean difference refers to the point estimates of the relative bioavailability. With its confidence intervals, it was obtained from the ANOVA model on the natural logarithm transformed data.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.6943</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.6438</ci_lower_limit>
            <ci_upper_limit>0.7487</ci_upper_limit>
            <estimate_desc>The mean difference refers to the point estimates of the relative bioavailability. With its confidence intervals, it was obtained from the ANOVA model on the natural logarithm transformed data.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.8389</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.6440</ci_lower_limit>
            <ci_upper_limit>1.0928</ci_upper_limit>
            <estimate_desc>The mean difference refers to the point estimates of the relative bioavailability. With its confidence intervals, it was obtained from the ANOVA model on the natural logarithm transformed data.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Pharmacodynamic Parameter Platelet Reactivity Index (PRI) From Vasodilator-stimulated Phosphoprotein (VASP) Phosphorylation State (Flow Cytometry).</title>
        <description>PRI is the platelet reactivity index from VASP phosphorylation state (flow cytometry).</description>
        <time_frame>24-hour post Day 9 dose in each period.</time_frame>
        <population>All participants who had valid parameter estimates for both regimens within a PPI group were included in the pharmacodynamics (PD) statistical analyses for this parameter.</population>
        <group_list>
          <group group_id="O1">
            <title>PPI Group 1: Regimen A</title>
            <description>Clopidogrel 75 mg, tablets, orally, once daily for up to 9 days.</description>
          </group>
          <group group_id="O2">
            <title>PPI Group 1: Regimen B</title>
            <description>Clopidogrel 75 mg, tablets, orally, once daily and Lansoprazole 30 mg, capsules, orally, once daily for up to 9 days.</description>
          </group>
          <group group_id="O3">
            <title>PPI Group 2: Regimen A</title>
            <description>Clopidogrel 75 mg, tablets, orally, once daily for up to 9 days.</description>
          </group>
          <group group_id="O4">
            <title>PPI Group 2: Regimen C</title>
            <description>Clopidogrel 75 mg, tablets, orally, once daily and Dexlansoprazole 60 mg, capsules, orally, once daily for up to 9 days.</description>
          </group>
          <group group_id="O5">
            <title>PPI Group 3: Regimen A</title>
            <description>Clopidogrel 75 mg, tablets, orally, once daily for up to 9 days.</description>
          </group>
          <group group_id="O6">
            <title>PPI Group 3: Regimen D</title>
            <description>Clopidogrel 75 mg, tablets, orally, once daily and Omeprazole 80 mg, capsules, orally, once daily for up to 9 days.</description>
          </group>
          <group group_id="O7">
            <title>PPI Group 4: Regimen A</title>
            <description>Clopidogrel 75 mg, tablets, orally, once daily for up to 9 days.</description>
          </group>
          <group group_id="O8">
            <title>PPI Group 4: Regimen E</title>
            <description>Clopidogrel 75 mg, tablets, orally, once daily and Esomeprazole 40 mg, capsules, orally, once daily for up to 9 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacodynamic Parameter Platelet Reactivity Index (PRI) From Vasodilator-stimulated Phosphoprotein (VASP) Phosphorylation State (Flow Cytometry).</title>
          <description>PRI is the platelet reactivity index from VASP phosphorylation state (flow cytometry).</description>
          <population>All participants who had valid parameter estimates for both regimens within a PPI group were included in the pharmacodynamics (PD) statistical analyses for this parameter.</population>
          <units>percent inhibition</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="38"/>
                <count group_id="O3" value="36"/>
                <count group_id="O4" value="36"/>
                <count group_id="O5" value="38"/>
                <count group_id="O6" value="38"/>
                <count group_id="O7" value="38"/>
                <count group_id="O8" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.3" spread="14.61"/>
                    <measurement group_id="O2" value="46.4" spread="16.44"/>
                    <measurement group_id="O3" value="41.3" spread="15.45"/>
                    <measurement group_id="O4" value="43.0" spread="16.47"/>
                    <measurement group_id="O5" value="47.9" spread="15.70"/>
                    <measurement group_id="O6" value="59.1" spread="17.87"/>
                    <measurement group_id="O7" value="46.5" spread="17.28"/>
                    <measurement group_id="O8" value="58.0" spread="14.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>4.1016</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.0348</ci_lower_limit>
            <ci_upper_limit>8.1684</ci_upper_limit>
            <estimate_desc>Included only participants with complete data for both regimens. Values are least squares mean difference.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>2.0474</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.8555</ci_lower_limit>
            <ci_upper_limit>4.9503</ci_upper_limit>
            <estimate_desc>Included only participants with complete data for both regimens. Values are least squares mean difference.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>11.0407</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>6.5219</ci_lower_limit>
            <ci_upper_limit>15.5595</ci_upper_limit>
            <estimate_desc>Included only participants with complete data for both regimens. Values are least squares mean difference.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>11.4437</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>7.1791</ci_lower_limit>
            <ci_upper_limit>15.7083</ci_upper_limit>
            <estimate_desc>Included only participants with complete data for both regimens. Values are least squares mean difference.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Pharmacodynamic Parameter Maximum Platelet Aggregation (MPA) From Aggregometry (Turbidimetric) With 5 µM Adenosine Diphosphate.</title>
        <description>Maximum platelet aggregation (MPA) from aggregometry (turbidimetric) with 5 µM adenosine diphosphate.</description>
        <time_frame>24-hour post Day 9 dose in each period.</time_frame>
        <population>All participants who had valid parameter estimates for both formulations within PPI groups were included in the PD statistical analyses for those parameters.</population>
        <group_list>
          <group group_id="O1">
            <title>PPI Group 1: Regimen A</title>
            <description>Clopidogrel 75 mg, tablets, orally, once daily for up to 9 days.</description>
          </group>
          <group group_id="O2">
            <title>PPI Group 1: Regimen B</title>
            <description>Clopidogrel 75 mg, tablets, orally, once daily and Lansoprazole 30 mg, capsules, orally, once daily for up to 9 days.</description>
          </group>
          <group group_id="O3">
            <title>PPI Group 2: Regimen A</title>
            <description>Clopidogrel 75 mg, tablets, orally, once daily for up to 9 days.</description>
          </group>
          <group group_id="O4">
            <title>PPI Group 2: Regimen C</title>
            <description>Clopidogrel 75 mg, tablets, orally, once daily and Dexlansoprazole 60 mg, capsules, orally, once daily for up to 9 days.</description>
          </group>
          <group group_id="O5">
            <title>PPI Group 3: Regimen A</title>
            <description>Clopidogrel 75 mg, tablets, orally, once daily for up to 9 days.</description>
          </group>
          <group group_id="O6">
            <title>PPI Group 3: Regimen D</title>
            <description>Clopidogrel 75 mg, tablets, orally, once daily and Omeprazole 80 mg, capsules, orally, once daily for up to 9 days.</description>
          </group>
          <group group_id="O7">
            <title>PPI Group 4: Regimen A</title>
            <description>Clopidogrel 75 mg, tablets, orally, once daily for up to 9 days.</description>
          </group>
          <group group_id="O8">
            <title>PPI Group 4: Regimen E</title>
            <description>Clopidogrel 75 mg, tablets, orally, once daily and Esomeprazole 40 mg, capsules, orally, once daily for up to 9 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacodynamic Parameter Maximum Platelet Aggregation (MPA) From Aggregometry (Turbidimetric) With 5 µM Adenosine Diphosphate.</title>
          <description>Maximum platelet aggregation (MPA) from aggregometry (turbidimetric) with 5 µM adenosine diphosphate.</description>
          <population>All participants who had valid parameter estimates for both formulations within PPI groups were included in the PD statistical analyses for those parameters.</population>
          <units>percentage of MPA</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="38"/>
                <count group_id="O3" value="36"/>
                <count group_id="O4" value="36"/>
                <count group_id="O5" value="37"/>
                <count group_id="O6" value="37"/>
                <count group_id="O7" value="38"/>
                <count group_id="O8" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.1" spread="6.76"/>
                    <measurement group_id="O2" value="30.8" spread="9.35"/>
                    <measurement group_id="O3" value="34.6" spread="14.23"/>
                    <measurement group_id="O4" value="36.2" spread="16.87"/>
                    <measurement group_id="O5" value="34.2" spread="12.32"/>
                    <measurement group_id="O6" value="42.5" spread="14.74"/>
                    <measurement group_id="O7" value="29.3" spread="10.41"/>
                    <measurement group_id="O8" value="38.2" spread="17.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.035</p_value>
            <p_value_desc>From ANOVA models in which the least-square means between two regimens are compared.</p_value_desc>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.445</p_value>
            <p_value_desc>From ANOVA models in which the least-square means between two regimens are compared.</p_value_desc>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>From ANOVA models in which the least-square means between two regimens are compared.</p_value_desc>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>From ANOVA models in which the least-square means between two regimens are compared.</p_value_desc>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Pharmacodynamic Parameter MPA From Aggregometry (Turbidimetric) With 20 µM Adenosine Diphosphate.</title>
        <description>MPA from aggregometry (turbidimetric) with 20 µM adenosine diphosphate.</description>
        <time_frame>24-hour post Day 9 dose in each period.</time_frame>
        <population>All participants who had valid parameter estimates for both formulations within PPI groups were included in the PK and PD statistical analyses for those parameters.</population>
        <group_list>
          <group group_id="O1">
            <title>PPI Group 1: Regimen A</title>
            <description>Clopidogrel 75 mg, tablets, orally, once daily for up to 9 days.</description>
          </group>
          <group group_id="O2">
            <title>PPI Group 1: Regimen B</title>
            <description>Clopidogrel 75 mg, tablets, orally, once daily and Lansoprazole 30 mg, capsules, orally, once daily for up to 9 days.</description>
          </group>
          <group group_id="O3">
            <title>PPI Group 2: Regimen A</title>
            <description>Clopidogrel 75 mg, tablets, orally, once daily for up to 9 days.</description>
          </group>
          <group group_id="O4">
            <title>PPI Group 2: Regimen C</title>
            <description>Clopidogrel 75 mg, tablets, orally, once daily and Dexlansoprazole 60 mg, capsules, orally, once daily for up to 9 days.</description>
          </group>
          <group group_id="O5">
            <title>PPI Group 3: Regimen A</title>
            <description>Clopidogrel 75 mg, tablets, orally, once daily for up to 9 days.</description>
          </group>
          <group group_id="O6">
            <title>PPI Group 3: Regimen D</title>
            <description>Clopidogrel 75 mg, tablets, orally, once daily and Omeprazole 80 mg, capsules, orally, once daily for up to 9 days.</description>
          </group>
          <group group_id="O7">
            <title>PPI Group 4: Regimen A</title>
            <description>Clopidogrel 75 mg, tablets, orally, once daily for up to 9 days.</description>
          </group>
          <group group_id="O8">
            <title>PPI Group 4: Regimen E</title>
            <description>Clopidogrel 75 mg, tablets, orally, once daily and Esomeprazole 40 mg, capsules, orally, once daily for up to 9 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacodynamic Parameter MPA From Aggregometry (Turbidimetric) With 20 µM Adenosine Diphosphate.</title>
          <description>MPA from aggregometry (turbidimetric) with 20 µM adenosine diphosphate.</description>
          <population>All participants who had valid parameter estimates for both formulations within PPI groups were included in the PK and PD statistical analyses for those parameters.</population>
          <units>percentage of MPA</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="38"/>
                <count group_id="O3" value="36"/>
                <count group_id="O4" value="36"/>
                <count group_id="O5" value="37"/>
                <count group_id="O6" value="37"/>
                <count group_id="O7" value="38"/>
                <count group_id="O8" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.7" spread="9.11"/>
                    <measurement group_id="O2" value="41.6" spread="12.65"/>
                    <measurement group_id="O3" value="43.1" spread="13.24"/>
                    <measurement group_id="O4" value="46.3" spread="16.93"/>
                    <measurement group_id="O5" value="43.5" spread="14.00"/>
                    <measurement group_id="O6" value="53.5" spread="13.75"/>
                    <measurement group_id="O7" value="39.3" spread="13.22"/>
                    <measurement group_id="O8" value="47.9" spread="15.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.004</p_value>
            <p_value_desc>From ANOVA models in which the least-square means between two regimens are compared.</p_value_desc>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.148</p_value>
            <p_value_desc>From ANOVA models in which the least-square means between two regimens are compared.</p_value_desc>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>From ANOVA models in which the least-square means between two regimens are compared.</p_value_desc>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <p_value_desc>From ANOVA models in which the least-square means between two regimens are compared.</p_value_desc>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Treatment-emergent adverse events are adverse events that started or worsened after the first dose of study drug and within 30 days after the last dose of study drug.</time_frame>
      <desc>At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study drug.</desc>
      <group_list>
        <group group_id="E1">
          <title>PPI Group 1: Regimen A</title>
          <description>Clopidogrel 75 mg, tablets, orally, once daily for up to 9 days.</description>
        </group>
        <group group_id="E2">
          <title>PPI Group 1: Regimen B</title>
          <description>Clopidogrel 75 mg, tablets, orally, once daily and Lansoprazole 30 mg, capsules, orally, once daily for up to 9 days.</description>
        </group>
        <group group_id="E3">
          <title>PPI Group 2: Regimen A</title>
          <description>Clopidogrel 75 mg, tablets, orally, once daily for up to 9 days.</description>
        </group>
        <group group_id="E4">
          <title>PPI Group 2: Regimen C</title>
          <description>Clopidogrel 75 mg, tablets, orally, once daily and Dexlansoprazole 60 mg, capsules, orally, once daily for up to 9 days.</description>
        </group>
        <group group_id="E5">
          <title>PPI Group 3: Regimen A</title>
          <description>Clopidogrel 75 mg, tablets, orally, once daily for up to 9 days.</description>
        </group>
        <group group_id="E6">
          <title>PPI Group 3: Regimen D</title>
          <description>Clopidogrel 75 mg, tablets, orally, once daily and Omeprazole 80 mg, capsules, orally, once daily for up to 9 days.</description>
        </group>
        <group group_id="E7">
          <title>PPI Group 4: Regimen A</title>
          <description>Clopidogrel 75 mg, tablets, orally, once daily for up to 9 days.</description>
        </group>
        <group group_id="E8">
          <title>PPI Group 4: Regimen E</title>
          <description>Clopidogrel 75 mg, tablets, orally, once daily and Esomeprazole 40 mg, capsules, orally, once daily for up to 9 days.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (13.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Serum sickness-like reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (13.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="39"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="16" subjects_at_risk="38"/>
                <counts group_id="E5" subjects_affected="14" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="11" subjects_at_risk="38"/>
                <counts group_id="E7" subjects_affected="17" subjects_at_risk="39"/>
                <counts group_id="E8" subjects_affected="15" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Ocular hyperaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Lacrimation increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="39"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Abdominal pain lower</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="39"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="39"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Feeling Hot</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Vessel puncture site pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="39"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="39"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="38"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="38"/>
                <counts group_id="E7" subjects_affected="6" subjects_at_risk="39"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="38"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Menorrhagia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="39"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Ecchymosis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="39"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="38"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Pruritus generalized</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Acne</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Rash papular</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Research Organization shall not publish any articles or papers nor make any presentations, nor assist any other person in publishing any articles or papers or in making any presentations relating or referring to the Study or any results, data or insights therefrom or any data, information or materials obtained or generated in the performance of it’s obligations without the prior written consent of Takeda, which consent may be granted or withheld in Takeda’s sole discretion.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Sr. VP, Clinical Science</name_or_title>
      <organization>Takeda Global Research and Development Center, Inc.</organization>
      <phone>800-778-2860</phone>
      <email>clinicaltrialregistry@tpna.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

